Abstracts tagged "Disease Activity"

Abstract Number: 1522 • 2016 ACR/ARHP Annual Meeting
Disease Burden in Rheumatoid Arthritis (RA) Patients Who Have Secondary Osteoarthritis (OA) Is Lower Than in OA but Higher Than in RA with No Secondary OA
Isabel Castrejón¹, Anne-Marie Malfait², Joel Block³ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Biochemistry & Rheumatology, Rush University Medical Center, Chicago, IL, ³Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Recent data indicate that the disease burden experienced by patients with osteoarthritis (OA) is similar to or greater than in rheumatoid arthritis (RA) (EULAR…
Abstract Number: 1757 • 2016 ACR/ARHP Annual Meeting
Association of the Lupus Low Disease Activity State (LLDAS) with Health-Related Quality of Life
Vera Golder¹, Rangi Kandane-Rathnayake², Alberta Y. Hoi³, Molla Huq⁴, Worawit Louthrenoo⁵, Yuan An⁶, Zhanguo Li⁶, Shue Fen Luo⁷, Sargunan Sockalingam⁸, Chak Sing Lau⁹, Mo Yin Mok¹⁰, Aisha Lateef¹¹, Kate Franklyn³, Susan Morton¹², Sandra V. Navarra¹³, Leonid Zamora¹³, Yeong-Jian Wu⁷, Laniyati Hamijoyo¹⁴, Madelynn Chan¹⁵, Sean O'Neill¹⁶, Fiona Goldblatt¹⁷, Mandana Nikpour¹⁸, Eric F Morand³ and Asia Pacific Lupus Collaboration, ¹Southern Clinical School, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Rheumatology, Monash University, Melbourne, Australia, ³Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁴Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ⁵Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁶Peking University People's Hospital, Beijing, China, ⁷Chang Gung University, Taoyuan County, Taiwan, ⁸University of Malaya, Kuala Lumpur, Malaysia, ⁹Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ¹⁰Queen Mary Hospital, Hong Kong, Hong Kong, ¹¹Medicine/Rheumatology, National University Health System, Singapore, Singapore, ¹²Monash Health, Melbourne, Australia, ¹³Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹⁴University of Padjadjaran, Bandung, Indonesia, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶University of New South Wales, Sydney, Australia, ¹⁷Royal Adelaide Hospital, Adelaide, Australia, ¹⁸Melbourne University, Melbourne, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant impairment of health-related quality of life (HR-QoL). Recently, meeting a definition of a Lupus Low Disease…
Abstract Number: 2230 • 2016 ACR/ARHP Annual Meeting
Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients
Brian Sauer¹, Chia-Chen Teng², Neil Accortt³, Zachary Burningham⁴, David Collier⁵, Mona Trivedi⁶ and Grant W. Cannon⁷, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Center for Observational Research, Amgen, Inc., C, CA, ⁴SLC Veterans Affairs Medical Center, SLC IDEAS Center, Salt Lake City, UT, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen, Thousand Oaks, CA, ⁷Internal Medicine, Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: The goal of this study was to validate a claims-based statistical model to predict disease activity measured by the 28-joint count Disease Activity Score…
Abstract Number: 2603 • 2016 ACR/ARHP Annual Meeting
Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone
Ara H. Dikranian¹, Rubaiya Mallay², Mike Marshall³, Megan Francis-Sedlak³ and Robert J. Holt^4,5, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Suncoast Internal Medicine Consultants and Largo Med Center, Largo, FL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Medical Affairs, Horizon Pharma, Inc, Lake Forest, IL, ⁵College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL
Background/Purpose: Patients with RA have previously demonstrated significant differences in morning stiffness (MS), a debilitating symptom of RA, and other disease measures with delayed release…
Abstract Number: 2818 • 2016 ACR/ARHP Annual Meeting
High Sensitivity Multiplex ELISA Reveals Cytokine Expression Heterogeneity in Active SLE
John A. Reynolds¹, Sahena Haque², Eoghan M. McCarthy³, Jamie C Sergeant⁴, Elaine Lee⁵, Eileen Holling Lee⁵, Steven Kilfeather⁵, Benjamin Parker⁶ and Ian N. Bruce⁷, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²Rheumatology department, University Hospitals of South Manchester NHS Foundation Trust, Manchester, United Kingdom, ³NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, ⁵Aeirtec Limited, UK, North Shields, United Kingdom, ⁶Centre for Musculoskeletal Research, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁷Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Patients with SLE have a broad clinical and immunological phenotype in which multiple immune pathways may be sequentially or simultaneously activated. No reliable biomarkers…
Abstract Number: 3087 • 2016 ACR/ARHP Annual Meeting
Association of Weight Loss with Improved Disease Activity in Patients with Rheumatoid Arthritis
David J. Kreps^1,2, Florencia Halperin³, Sonali P. Desai³, Zhi Zhang³, Elena Losina³, Elizabeth W. Karlson¹, Bonnie L. Bermas¹ and Jeffrey A. Sparks⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Boston University, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose : Obesity has been associated with worsened RA outcomes and increased disease activity. However, few longitudinal studies have investigated whether weight loss might improve…
Abstract Number: 136 • 2016 ACR/ARHP Annual Meeting
The 7-Joints Musculoskeletal Ultrasound Score (US7 score) Predicts Therapeutic Change in Patients with Early Rheumatoid Arthritis
Sarah Ohrndorf¹, Philipp Daniel Oberdorfer², Lien Le³, Ulrich Mansmann³, Lisa Ines Sprenger², Thomas Häupl⁴, Sandra Hermann², Gabriela Schmittat², Silvia Pade², GR Burmester⁵, Anne-Marie Glimm² and Marina Backhaus⁶, ¹Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ³Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität Munich, Munich, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁵Charité – University Medicine Berlin, Berlin, Germany, ⁶Department of Rheumatology & Immunology, University Medicine Charit, Berlin, Germany
Background/Purpose: Treatment decisions in patients with Rheumatoid Arthritis (RA) after the “Treat to Target (T2T)” - principle is widely recommended, as this management strategy leads…
Abstract Number: 527 • 2016 ACR/ARHP Annual Meeting
The Summed Bilateral Elbow Extension Angle in Rheumatoid Arthritis Correlates with the DAS28-CRP(4) and May be an Independent Marker of Bad Prognosis
John P. Case¹, Congbin Wang² and Heidi Tucker³, ¹Internal Medicine/Rheumatology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Internal medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ³Rush Medical College, Chicago, IL
Background/Purpose: The elbow is an easily-examined joint and an important determinant of morbidity in rheumatoid arthritis (RA). In active RA the measured elbow extension angle,…
Abstract Number: 787 • 2016 ACR/ARHP Annual Meeting
Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Measure Disease Severity in Discoid Lupus Erythematosus
Jenna K. Presto^1,2, Jessica S. Haber^1,2 and Victoria P. Werth^1,2, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Discoid lupus erythematosus (DLE) progresses to systemic lupus erythematosus (SLE) in up to 28% of cases. The Systemic Lupus International Collaborating Clinics (SLICC) SLE…
Abstract Number: 1361 • 2016 ACR/ARHP Annual Meeting
The Role of Von Willebrand Factor Antigen As a Disease Biomarker in the Clinical Assessment of Children with Juvenile Dermatomyositis
Dawn Wahezi¹, Vito Arena², Jaeun Choi² and Qi Gao², ¹Pediatric Rheumatology, The Children's Hospital at Montefiore, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: With the advent of new therapies, outcomes for children with juvenile dermatomyositis (JDM) have significantly improved. Accurate markers of clinically inactivedisease are thus fundamental…
Abstract Number: 1526 • 2016 ACR/ARHP Annual Meeting
Serum y-Neuropeptide Levels and Its Relationship with Body Fat Mass and Clinical Characteristics in Rheumatoid Arthritis
Melissa Ramirez-Villafaña¹, Paulina Hernandez-Cuervo², Ana Miriam Saldaña-Cruz³, Edsaul Emilio Perez-Guerrero^4,5, Nicte Selene Fajardo-Robledo⁶, Edy David Rubio-Arellano⁷, Alejandra Flores-Chavez⁸, Javier Alejandro Aceves-Aceves^9,10, Arnulfo Hernan Nava-Zavala¹¹, Mario Salazar-Paramo¹², Miguel Huerta¹³, Miriam Fabiola Alcaraz-Lopez¹⁴, Jorge Ivan Gamez-Nava¹⁵ and Laura Gonzalez-Lopez¹⁶, ¹Departamento Medicina Interna-Reumatología, Instituto Mexicano del Seguro Social, Hospital General Regional 110, Jalisco, Mexico, ²Programa de Doctorado en Ciencias de la Salud Pública, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara. Guadalajara, Jalisco, México., Guadalajara, Mexico, ³Centro Universitario de Investigación Biomédica. Universidad de Colima, Colima, Mexico, ⁴Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁵Doctorado en Farmacología, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico, ⁶Laboratorio de Investigación y Desarrollo Farmacéutico, Universidad de Guadalajara, Centro Universitario de Ciencias Exactas e Ingenierias, Jalisco, Mexico, ⁷Centro Universitario de Investigación Biomédica. Universidad de Colima., Colima, Colima, Mexico, ⁸Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁹Departamento de Medicina Interna-Reumatologia, Hospital General Regional 110, IMSS, Guadalajara, Jalisco, Mexico, ¹⁰Posgrado de Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara., Guadalajara, Jalisco, Mexico, ¹¹Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Jalisco, Mexico, ¹²Physiology, HSC, University of Guadalajara, Guadalajara, Mexico, ¹³Centro Universitario de Investigación Biomédica, Universidad de Colima, Colima, Mexico, ¹⁴Departamento Medicina Interna-Reumatología, Instituto Mexicano del Seguro Social, Hospital General Regional 45, Jalisco, Mexico, ¹⁵Rheumatology, Centro Medico de Occidente, Guadalajara Jal, Mexico, ¹⁶Departamento de Medicina Interna/Rheumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico
Background/Purpose: Overweight and obesity are comorbidities that may increase the risk of cardiovascular disease in rheumatoid arthritis. Increase in in body fat is observed in…
Abstract Number: 1795 • 2016 ACR/ARHP Annual Meeting
Four Years Follow-up of Subclinical Atherosclerosis in Systemic Lupus Erythematosus Patients
Ju-Yang Jung¹, Hyoun-Ah Kim¹ and Chang-Hee Suh², ¹Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ²Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, The Republic of
Background/Purpose: We assessed carotid artery intima-media thickness (cIMT) and carotid plaque by Doppler ultrasonography among sixty-one female SLE patients who were enrolled in the previous…
Abstract Number: 2444 • 2016 ACR/ARHP Annual Meeting
Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis
Emily Fishman¹, Kathryn H. Dao² and John J. Cush³, ¹Texas A&M HSC College of Medicine, Dallas, TX, ²Texas Health, Dallas, TX, ³Baylor Research Institute, Dallas, TX
Background/Purpose: Pregnancy is often encountered in women who have inflammatory arthritis (IA), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile arthritis (JIA) or ankylosing…
Abstract Number: 2624 • 2016 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibodies Titers Are Independently Modulated By Disease Activity and Synthetic or Biologic Dmards in a Seropositive Early Arthritis Population
Elena García Lorenzo¹, Daniel Useros², Aranzazu Alfranca³, Ana M. Ortiz Garcia¹, Pablo Moreno Fresneda¹, Isidoro Gonzalez-Alvaro¹ and Rosario García-Vicuña¹, ¹Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ²Rheumathology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ³Immunology, Immunology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain
Background/Purpose: Early introduction of some biologic (b) DMARDs has been proposed to reduce anti-citrullinated protein antibodies (ACPA) titers in clinical trials settings. However, less information…
Abstract Number: 2822 • 2016 ACR/ARHP Annual Meeting
Serum 25-Hydroxyvitamin D3 Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
Chi Chiu Mok¹, Eric Bro², Ling Yin Ho³, Ravinder Singh² and Paul Jannetto⁴, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ⁴Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic, Rochester, MN
Background/Purpose: To study the relationship between serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus (SLE) in a longitudinal cohort of Chinese patients. Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].